HSINCHU, Taiwan, Feb. 29, 2016 /PRNewswire/ -- JHL Biotech, Inc. (Stock Code: 6540.TWO) announced it has entered into a contract manufacturing master service agreement with Affinita Biotech. The agreement covers a development and manufacturing partnership for Affinita's oncology monoclonal antibodies.
The agreement, extending to 2020, is estimated to be worth up to US$20 million in value. JHL will provide cell line development, process development, and manufacturing expertise. The activities will be carried out in JHL's Zhubei site in Taiwan as well as at JHL's manufacturing facility in Wuhan, China.
About Affinita Biotech
Affinita Biotech, based in South San Francisco, California, is a preclinical stage biotech company focusing on research and development of certain novel cancer therapies. The company was founded in 2015 by a group of industry experts to focus on research and development of targeted, immunity-based oncology therapies.
About JHL Biotech
JHL Biotech was founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is supported by the commitment of premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech's mission is to provide the world with low-cost medicines of exceptional quality.
JHL Biotech has built world-class facilities in accordance with United States, European Union, and ICH cGMP regulations and standards. The JHL Center of Excellence in Taiwan can support biosimilar pre-clinical and early-clinical phase R&D work; JHL's facility in Wuhan, China will be able to support commercial-scale manufacturing of biologic therapies. This infrastructure gives JHL the unique ability to manufacture its own product and execute contract orders for select clients. For more information about JHL Biotech, please visit the JHL Biotech website at www.jhlbiotech.com.
Media Contact:
JHL Biotech, Inc.
Max Chan, Chief Financial Officer
Contact Phone Number: +886-(0)3-658-3899 #700
Contact Email: [email protected]